Envestnet Asset Management
AKRO

Envestnet Asset Management’s Akero Therapeutics AKRO Stock Holding History

Envestnet Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,740
Closed -$367K – 4453
2025
Q3 		$367K Sell
7,740
-1,865
-19% -$90.3K ﹤0.01% 3954
2025
Q2 		$513K Sell
9,605
-3,729
-28% -$169K ﹤0.01% 3669
2025
Q1 		$540K Buy
13,334
+3,170
+31% +$134K ﹤0.01% 3577
2024
Q4 		$283K Sell
10,164
-544
-5% -$16.5K ﹤0.01% 3921
2024
Q3 		$307K Buy
+10,708
New +$279K ﹤0.01% 3808
2024
Q2 		– Sell
-14,427
Closed -$364K – 4165
2024
Q1 		$364K Buy
+14,427
New +$347K ﹤0.01% 3621
2023
Q4 		– Sell
-9,426
Closed -$477K – 4046
2023
Q3 		$477K Buy
+9,426
New +$439K ﹤0.01% 3283

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Envestnet Asset Management's AKRO Position: Q4 2025 in Review

Envestnet Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 7,740 shares — an estimated $367K sold.

Envestnet Asset Management first reported a position in AKRO in Q3 2023 and held it in 7 quarters. The position peaked at $540K in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Envestnet Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 7,740 Akero Therapeutics shares in Q4 2025, an estimated $367K.
  • Envestnet Asset Management first reported a position in Akero Therapeutics in Q3 2023 and held it in 7 quarters.
  • Envestnet Asset Management's Akero Therapeutics position peaked at $540K in Q1 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Envestnet Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.